Hydroxychloroquine in Mild Graves' Orbitopathy
A legfontosabb adatok
- Fázis
- 4. fázis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálat adatai
- Ki végzi
- National Taiwan University Hospital
- Azonosító
- NCT05126147
- A regiszteradat frissítve
- 2026. november 2.
- Eredeti leírás
This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).A teljes eredeti leírásKevesebb
A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Mild Graves' Orbitopathy
This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).
Bevonási feltételek: Mild GO according European Group on Graves' orbitopathy (EUGOGO) guidelines diagnosed by endocrinologist and ophthalmologist; No previous treatment of GO except for eyedrops; Euthyroidism (normalized free T4 and TSH) for at least 2 months. If radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months.
Kizáró feltételek: Drug or alcohol abuse; Use of hydroxychloroquine or systemic steroid within 3 months prior to enrollment; History of side effects of hydroxychloroquine; History of retinopathy; Allergy to 4-aminoquinoline; Renal dysfunction (estimated glomerular filtration rate (eGFR) < 60ml/min); Hepatic dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x upper limit); Anemia (hemoglobin (Hb) < 10g/dl); Neutropenia (absolute neutrophil count < 100/uL); Thrombocytopenia (platelet (PLT) < 150000/uL); Glucose-6-phosphate dehydrogenase (G6PD) deficiency; Moderate-to-sever or sight-threatening GO according to EUGOGO guidelines diagnosed by endocrinologist and ophthalmologist; Pregnancy; Unable to comply with the study protocol; Unable to obtain informed consent; Porphyria cutaneous tarda.